Home > News > pSivida Signs Licensing Agreement with Faber Research LLC
January 9th, 2007
pSivida Signs Licensing Agreement with Faber Research LLC
Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced it has entered into a licensing agreement with US-based Faber Research LLC (Faber) to develop pSivida's proprietary Durasert™, Zanisert™ and Co-Drug™ drug delivery technologies for infectious diseases and diseases of the ear.
This announcement follows an announcement on December 26, 2006 that pSivida entered into an exclusive negotiation period with a major global pharmaceutical company to acquire a worldwide, royalty bearing license to make, use and sell products using pSivida's drug delivery technologies. The pharmaceutical company will make payments totalling US$990k (AU$1.3m) to pSivida for the right to exclusively negotiate a licensing agreement with the Company for a period of three months and to fund the cost of a preclinical study. The commencement of licensing negotiations follows a 12 month evaluation of pSivida's technologies by the large global pharmaceutical company.
Treatment of Cell Infection by Nanotechnology September 15th, 2014
Researchers Create World’s Largest DNA Origami September 11th, 2014
Iranian Scientists Discover Nanotechnology Method to Remove Limitations in Tumor Surgery September 11th, 2014
Iranian Nanotechnology Scientists Produce Polymeric Scaffolds for Tissue Engineering September 11th, 2014
Carbon Sciences Developing Breakthrough Technology to Mass-Produce Graphene -- the New Miracle Material: Company Enters Into an Agreement With the University of California, Santa Barbara (UCSB) to Fund the Further Development of a New Graphene Process September 16th, 2014
Nanoribbon film keeps glass ice-free: Rice University lab refines deicing film that allows radio frequencies to pass September 16th, 2014
Effective Nanotechnology Innovations to Receive Mustafa Prize September 16th, 2014
‘Small’ transformation yields big changes September 16th, 2014